Jose Luis Górriz
@jlgorriz
Followers
9K
Following
10K
Media
872
Statuses
5K
Jefe de Servicio de Nefrología. Prof. Contratado Doctor Medicina. Investigador. Ex-Presidente de la Soc Valenciana de Nefrologia. Aficionado a la musica y arte.
Valencia, España
Joined September 2013
Every diabetic patient deserves a triple shield: RASi + SGLT2i + nsMRA. Early detection and rapid implementation = decades of kidney and cardiovascular protection. @jlgorriz @IntDiabetesFed @scottisaacsmd @DanielJDrucker
@EndoConnect @IndiaESI @Rssdi_official
@kamleshkhunti
2
26
48
UTI is uncommon with SGLT2i - mycotic infections are common This study has important clinical implications ⚠️ After UTI, 1 in 3 patients stopped SGLT2i Discontinuation led to higher CV & renal risk, with no reduction in recurrent UTIs. 💡 Following UTI - continue SGLT2i
7
90
325
🆕Advancing Timely Implementation of triple therapy in DM2 and CKD ✅Necesidad de implementación rápida de iSRAA+iSGLT2+nsARM ✅🛑12 años llegada ERT ✅Seguridad 👍🏻 👇🏼👇🏼👇🏼 https://t.co/aS7yDofgz7
@beaff26 @jlgorriz @anicebrian @mi_cardiologo Dr Alberto Ortiz, Dr M.P. Maver
0
22
52
Chat isn’t going anywhere. Mike Krieger (CPO, Anthropic) explains why the chat interface is still the most powerful way to work with AI — and how it’s evolving to feel more like talking to a coworker.”
1
1
13
Proud of our new article! Don’t let therapeutic inertia steal time from our patients. Early detection of albuminuria and fast triple therapy (RASi + SGLT2i + Finerenone) can delay kidney failure by up to a decade. 👉 https://t.co/Y5gGGiQMMO 🙂 @SENefrologia @ERAkidney @ASNKidney
0
40
135
Excited to kick off the #CAPTIVATE study! A new way to design and run clinical trials in #Nephrology. Proud that our centre is now active. https://t.co/ihfa5Lkg6n Rationale 👉 https://t.co/wanG5AbJSI
@GVAclinic @incliva_iis @umcg
@georgeinstitute @SENefrologia #ClinicalTrials
1
4
12
Os emplazamos a la lectura de este paper de actualidad que visibiliza la "alianza" entre la enfermedad cardiovascular, la enfermedad renal y la #MASLD. Realidad cada vez más prevalente en nuestras consultas, pero con un futuro de abordaje prometedor.❤️ https://t.co/BIAGVXj6Zn
0
31
98
Congestion as a crucial factor determining albuminuria in patients with cardiorenal disease https://t.co/XxJoaUoq3p
1
10
36
Happy to share our findings on glucose interference in urine biomarkers and what it means for research and practice in the era of #SGLT2i (@KIReports). https://t.co/Y8ZvooNeuK
#NephTwitter #biomarkers #glycosuria #flozins
@Oxford_NDPH @willkidney
1
3
8
Preventing chronic kidney disease and maintaining kidney health: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference Post hoc analyses of clinical trials suggest pharmacological interventions, such as sodium-glucose cotransporter-2
0
30
80
Almost all u need 2 know about the remarkable clinical effects of #SGLT2i on the kidney in a wide ranging IPD metaanalysis (covers effects by albuminuria, predicted eGFR dip and novel exploratory eGFR slope methods). Please do read it! @Oxford_NDPH @NatalieStaplin @MartinLandray
New—Effects of #empagliflozin on conventional and exploratory acute and chronic #kidney outcomes: an individual participant-level meta-analysis https://t.co/e1njA9oRmo
#SGLT2 inhibitor #CKD
#OpenAccess
0
6
21
🌍 #SaludRenal | La ERC podría ser la tercera causa de muerte en España en 2050. En “La Clave de FI: Confidence Edition”, especialistas pidieron replantear su abordaje desde fases iniciales y con terapias eficaces @BayerEspana @Hospital_FJD @jlgorriz https://t.co/fOLdDOOFXN
isanidad.com
Bayer ha celebrado un encuentro científico para debatir sobre los avances en el abordaje en diabetes tipo 2 y enfermedad renal crónica
0
3
8
🔬 Damos la bienvenida al Dr. Enrique Rodríguez Borja (@arropT) como nuevo Jefe de Servicio de Bioquímica Clínica en el @GVAclinic Su experiencia en comisiones nacionales e internacionales, docencia e investigación refuerza nuestro compromiso con la excelencia diagnóstica💙
7
5
20
2025 Update on resistant hypertension in CKD: where do we stand and where do we go? 🔓 https://t.co/d11XPH0nfy
0
145
369
Glycosuria interferes with IL-18 and YKL-40 assays…..NGAL, UMOD, MCP-1, KIM-1, EGF, DKK-3 reasonably reliable (at least in our assays). Glucose interference experiments need to be the norm for urine assays in the era of SGLT2i. @grecombm @KIReports
Happy to share our findings on glucose interference in urine biomarkers and what it means for research and practice in the era of #SGLT2i (@KIReports). https://t.co/Y8ZvooNeuK
#NephTwitter #biomarkers #glycosuria #flozins
@Oxford_NDPH @willkidney
0
7
22
Para los que estéis por Valencia: Sábado 4 de octubre, 14 h. Concierto con nuestra banda de Soul-Funk. Restaurante La Ferradura (Playa Patacona) https://t.co/7Z39AYn5ce Comida, tardeo & mucho soul-funk 💃🕺 Reservas: Telf 963716484 Info👉 https://t.co/Ifxy5c729Z ¡Os esperamos!🙌
drive.google.com
0
0
7
📢REVIEW: 🔀Interconnections between: ➡️Metabolic dysfunction-associated steatotic liver disease (MASLD) ➡️Chronic Kidney Disease ➡️Cardiovascular Risk Open: https://t.co/v8BXrjWeva
#fattyLiver #MASLD #NAFLD #diabetic @SENefrologia @jlgorriz @AEEHLiver @sociedadSEEN
1
4
18
1
10
47
The effect of GLP-1 receptor agonists on renal outcomes: a systematic review and meta-analysis https://t.co/0lJ6gZ0GwZ
0
22
61
KDIGO is excited to share the publication of the 2025 Clinical Practice Guideline for the Management of IgA Nephropathy (#IgAN) and IgA Vasculitis (#IgAV), along with the Executive Summary in @Kidney_Int. Read the Guideline in KI: https://t.co/Ygwhu3rizm Download the Executive
1
151
334
In a world built for humans, humanoid robots are designed to plug right into existing infrastructure. In a recent webinar, KraneShares CIO @ahern_brendan, Senior Investment Strategist Derek Yan, CFA, and Robostore Founder Teddy Haggerty explored why they believe this simple fact
4
19
67